Calcium and Vitamin D Supplementation for Cancer Patients
Cancer patients should take 1,200 mg of calcium (from all sources) and 800-1,000 IU of vitamin D daily for general health, but must have serum calcium levels monitored due to increased risk of hypercalcemia. 1
Core Supplementation Recommendations
The NCCN Bone Health in Cancer Care Task Force specifically recommends these ranges for cancer patients at risk for treatment-associated bone loss 1. The ASCO guideline reinforces this, stating that if dietary intake of calcium (1,000-1,200 mg/d) and vitamin D (at least 800-1,000 IU/d) is insufficient, supplements to reach those levels are recommended 2.
Vitamin D Dosing Based on Lab Values
Check serum 25(OH)D levels before supplementing. The target is ≥30 ng/mL (75 nmol/L) for optimal bone health 1, 3.
For deficient patients (25(OH)D <30 ng/mL):
- Prescription vitamin D (ergocalciferol) 50,000 IU weekly for 8 weeks
- Recheck serum 25(OH)D level after 8 weeks
- Adjust subsequent dosing based on results 1
For borderline patients (25(OH)D 20-30 ng/mL):
- Add 1,000 IU over-the-counter vitamin D2 or D3 daily
- Recheck level in 3 months 1
Maintenance after repletion:
- 800-1,000 IU daily for most patients
- Some patients may require 3,000-6,000 IU daily to maintain levels >30 ng/mL 4
Critical Safety Considerations: Hypercalcemia Risk
This is where cancer patients differ critically from the general population. Hypercalcemia occurs in 10-25% of cancer patients, most commonly with squamous cell lung cancer 5. Multiple mechanisms can cause hypercalcemia in cancer:
Monitor Serum Calcium Regularly
Before starting supplementation, check:
- Serum calcium (corrected for albumin)
- Serum 25(OH)D
- Intact PTH
- Consider PTH-related protein (PTHrP) if calcium elevated 5, 6
During supplementation, monitor calcium levels every 3-6 months, or more frequently if:
- Patient has bone metastases
- Patient is on bisphosphonates or denosumab
- Baseline calcium is in upper normal range
- Patient has granulomatous disease (sarcoidosis, tuberculosis) 4, 7
When to Avoid or Reduce Supplementation
Do not supplement calcium/vitamin D if:
- Serum calcium >10.5 mg/dL (2.6 mmol/L)
- History of hypercalcemia of malignancy
- Active hypercalcemia from any cause 8, 6
Use caution and lower doses if:
- Patient has lymphoma or multiple myeloma (can produce ectopic 1,25(OH)2D) 7, 9
- Patient has granulomatous disease
- Serum 25(OH)D is already >30 ng/mL 4
Special Consideration for Patients on Bisphosphonates
If the patient is receiving bisphosphonates or denosumab for bone metastases, calcium and vitamin D supplementation is actually required to prevent treatment-induced hypocalcemia 1, 10. However, this creates a paradox requiring careful monitoring. The standard approach:
- Ensure adequate calcium (1,200 mg/d) and vitamin D (800-1,000 IU/d)
- Monitor calcium levels closely (every 2-4 weeks initially)
- Adjust supplementation based on calcium levels 1
Practical Algorithm
- Baseline labs: Serum calcium (corrected), 25(OH)D, intact PTH
- If calcium normal and 25(OH)D <30 ng/mL:
- Start calcium 1,200 mg/d (from diet + supplements)
- Start vitamin D 800-1,000 IU/d (or higher dose repletion if <20 ng/mL)
- Recheck labs in 3 months: Calcium and 25(OH)D
- Adjust based on results:
- If 25(OH)D still <30 ng/mL: increase vitamin D dose
- If calcium elevated: reduce or stop calcium supplements, reduce vitamin D
- If both optimal: continue maintenance dosing
- Ongoing monitoring: Calcium every 3-6 months, 25(OH)D annually
Common Pitfalls to Avoid
Do not assume supplements are safe because they're "natural." Case reports document symptomatic hypercalcemia in cancer patients taking calcium, vitamin D, or shark cartilage supplements 11. The risk is real and potentially life-threatening.
Do not supplement vitamin D beyond 1,000 IU daily without checking levels first in cancer patients, given their increased baseline hypercalcemia risk 1, 2.
Do not ignore symptoms of hypercalcemia: polyuria, polydipsia, nausea, confusion, constipation, abdominal pain. These require immediate calcium level check 5.
Vitamin D toxicity is uncommon but occurs with daily doses >50,000 IU producing 25(OH)D levels >150 ng/mL, causing hypercalcemia, hyperphosphatemia, and bone resorption 1.